425: Mentari Therapeutics Appoints New CEO Amid Merger Talks

Mentari Therapeutics announces Greg Divis as new CEO, advancing migraine therapies as it merges with InMed Pharmaceuticals.

Summary

• Mentari Therapeutics has appointed Greg Divis as its new Chief Executive Officer and a member of the Board of Directors, effective July 20, 2026.
• This appointment occurs in the context of a proposed merger between InMed Pharmaceuticals Inc. and Mentari Therapeutics, Inc., as outlined in an Agreement and Plan of Merger and Reorganization dated May 19, 2026.
• Mentari is developing therapies for migraine prevention, with lead programs MT-001 (an anti-PACAP antibody) and MT-002 (an anti-PACAP and anti-CGRP bispecific antibody).
• Regulatory filings for MT-001 are anticipated in 2026, and for MT-002 in Q1 2027.
• Greg Divis brings extensive experience, including his previous role as CEO of Avadel Pharmaceuticals, where he oversaw the development, FDA approval, and commercial launch of Lumryz, and its subsequent sale to Alkermes for up to $2.4 billion.
• The merger involves InMed Pharmaceuticals, its subsidiaries Indigo Merger Sub Corp. and Indigo Merger Sub II, LLC, and Mentari Therapeutics.
• InMed has filed a registration statement on Form S-4 with the SEC, which includes a preliminary proxy statement/prospectus and management information circular.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the strong CEO appointment and clear pipeline progression, though the merger's success remains contingent on regulatory and shareholder approvals.

Positives

• Appointment of Greg Divis, an industry veteran with a proven track record in leadership, M&A, and commercial success, as CEO.
• Divis's experience includes successfully leading Avadel Pharmaceuticals through development, FDA approval, and commercial launch of Lumryz, and its sale to Alkermes for up to $2.4 billion.
• Mentari's pipeline targets PACAP and CGRP pathways, which are validated targets for migraine prevention.
• MT-002 is designed for convenient subcutaneous delivery, potentially offering an advantage in migraine treatment.
• The company is on track for regulatory filings for its lead drug candidates in 2026 and Q1 2027.

Negatives

• The merger is subject to satisfaction or waiver of conditions, including shareholder approvals and regulatory effectiveness of the Form S-4.
• There is a risk that the merger may not be completed on the anticipated timeline or at all.
• The success of the drug candidates MT-001 and MT-002 is subject to the inherent risks of preclinical and clinical development, regulatory review, and commercialization.
• The filing mentions risks related to redomestication, reverse stock split, and Nasdaq continued-listing requirements.

Risks

• The risk that the merger may not be completed on the anticipated timeline or at all.
• Failure to obtain required InMed shareholder and Mentari stockholder approvals.
• Failure to satisfy other closing conditions, including the effectiveness of the registration statement on Form S-4.
• The risk that any concurrent financing is not completed on the expected terms or at all.
• Risks relating to the redomestication, reverse stock split, and Nasdaq continued-listing requirements.
• Risks inherent in preclinical and clinical development, the regulatory review and approval process, and commercialization of product candidates.
• Potential for actual results to differ materially from forward-looking statements due to various uncertainties.

Future Outlook

Mentari Therapeutics is on track for regulatory filings for MT-001 in 2026 and MT-002 in Q1 2027. The company aims to advance these therapies through clinical development and position itself as a leader in migraine prevention. The merger with InMed Pharmaceuticals is expected to bring anticipated benefits, though specific financial projections are not detailed in this communication.

Management Comments

• "Greg brings proven experience to Mentari during its foundational period of growth. He is the ideal choice to lead as we rapidly advance MT-001 and MT-002 through clinical development and position Mentari as a leader in migraine prevention."
• "His experience successfully commercializing Lumryz and delivering on the acquisition by Alkermes demonstrates his ability to build shareholder value while also delivering meaningful therapies for patients."
• "Mentari's approach to migraine prevention, initially targeting the complementary and validated PACAP and CGRP pathways, represents an opportunity to deliver enhanced migraine relief for patients who continue to suffer with the current standard of care."
• "With MT-002 also designed for convenient subcutaneous delivery, Mentari is well-positioned to lead the next wave of migraine treatment."
• "I am excited about Mentari's entire pipeline, which offers a clear path to value creation, as well as versatility through its novel targets and potential to build next-generation combination therapies that may deliver migraine freedom to more patients. I am honored to join this talented team."

Industry Context

StockSavvy.ai notes that the appointment of an experienced CEO like Greg Divis, particularly one with a successful track record in drug commercialization and M&A, is a positive signal for Mentari Therapeutics. This move, coupled with the advancement of novel migraine therapies targeting PACAP and CGRP, aligns with the broader trend in the pharmaceutical industry of focusing on unmet medical needs and developing targeted treatments for complex conditions. The merger with InMed Pharmaceuticals suggests a strategic consolidation aimed at leveraging combined resources for further development and market entry.

Management Changes

Stakeholder Impact

• Shareholders of InMed and Mentari: The merger aims to create value, but success depends on closing conditions and future performance of the combined entity. Shareholders will vote on the merger.
• Employees of Mentari: The appointment of a new CEO and the ongoing merger may lead to changes in organizational structure and strategy.
• Patients: The development of MT-001 and MT-002 offers potential new therapeutic options for migraine prevention, addressing an unmet medical need.

Next Steps

• Completion of the merger between InMed Pharmaceuticals and Mentari Therapeutics.
• Advancement of MT-001 through regulatory filings in 2026.
• Advancement of MT-002 through regulatory filings in Q1 2027.
• Shareholders of InMed and Mentari to review the definitive proxy statement/prospectus and management information circular once available.

Key Dates

Recommendation

The filing announces a significant strategic development with the appointment of a strong CEO and progress in drug development, alongside a pending merger. While positive, the outcome of the merger and the success of the drug candidates are subject to substantial risks and regulatory approvals, warranting a 'hold' position until more clarity emerges.

Keywords

Mentari Therapeutics, InMed Pharmaceuticals, Merger, Greg Divis, CEO Appointment, Migraine Prevention, Biotechnology, Clinical Development